What is the long-term trend for Viridian Therapeutics, Inc.'s research and development expense?

Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s research and development expense has grown at a 56.2% compound annual growth rate (CAGR), from $56.89M to $338.93M.

Viridian Therapeutics, Inc. VRDN Research and development expense

Research and development expense at other companies

Johnson & JohnsonJNJ

$3.53B+9.4%

AmgenAMGN

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Enterprise value$1.77B+85.0%

P/S26.9×-3,445×

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s research and development expense?: Viridian Therapeutics, Inc. (VRDN) reported research and development expense of $77.63M in Q1 2026.
How has Viridian Therapeutics, Inc.'s research and development expense changed year-over-year?: Viridian Therapeutics, Inc.'s research and development expense increased by 1.0% year-over-year, from $76.84M to $77.63M.
What is the long-term trend for Viridian Therapeutics, Inc.'s research and development expense?: Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s research and development expense has grown at a 56.2% compound annual growth rate (CAGR), from $56.89M to $338.93M.